Author (year)
Study design
No. patients
No. patients
No. patients
No. patients
Age
Female
Symptoms
AVA (cm2)
SVi (mL/m2)
Mean gradient (mmHg)
LVEF (%)
Classical LFLGAS/Paradoxical LFLGAS
CAD
Follow up (months)
AVR AVR noAVR
Hachicha et al. (2007) RCS 171 80 91 91 73±13 92 (51) - 0.76±0.23 - 32±17 62±8 Paradoxical LFLGAS 46 (65) 60*
Clavel et al. (2008) MPOS 101 44 57 57 71±10 23 (23) 49 (49) 0.92±0.24 - 21±8 29±9 Classical LFLGAS 76 (75) 20±15
Pai et al. (2008)
RCS
167
46
121
121
72±13
-
-
-
-
-
-
Classical LFLGAS: 115 (68.9) Paradoxical LFLGAS: 52 (31.1)
-
28.8±32.4
Tarantini et al. (2011) RCS 101 72 29 29 78 [72–81] 59 (58) 90 (88) 0.80 [0.70-0.89] 46 ±13 33 [27–38] 0.69 [0.61–0.74] Paradoxical LFLGAS 63 (62.4) 42 [23-75]
Clavel et al. (2012)
RCS
187
83
104
104
74 ±12
96 (51)
44 (22)† 104 (56)‡
0.82 ± 0.16
30 ± 4
22±8
62±8
Paradoxical LFLGAS
120 (64)
50.4±28.8
Mohty et al. (2013) RCS 99 83 16 16 77±6 50 (51) 88 (89) 0.72±0.17 29±5 30±7 70±11 Paradoxical LFLGAS 54 (54.5) 55.2±36
Melis et al. (2013) RCS 40 18 22 22 78 [73.0-83.0] 25 (59.5) - 0.77 [0.73-0.81] 31 [30-32] 26 [24-29] 64 [62-67] Paradoxical LFLGAS 22 (55) 26.1 [14.6-36.1]
Herrmann et al. (2013) RCS 130 105 25 25 - - - - - - - Classical LFLGAS - 24*
Eleid et al. (2013) RCS 53 27 26 26 77±12 18 (34) 41 (77) 0.87±0.11 31±3 30±6 60±7 Paradoxical LFLGAS 23 (43) 27.6±22.8
Ozkan et al. (2013) PCS 135 54 81 81 - - - - - - - Paradoxical LFLGAS - 60*
Tribouilloy et al. (2015) RCS 114 57 57 57 78.5 [73.5–86.3] 33 (57.9) 9 (15.8) 0.8 [0.7–0.9] 30.1 [27.2–32.2] 30 [20.5–34.5] 60 [55–67] Paradoxical LFLGAS 22 (13.3) 39 [11-69]
Annabi et al. (2019)
PCS
480
269
211
211
75 ± 10
136 (28.3)
0.79±0.15
-
26±7
-
Classical LFLGAS: 341 (71) Paradoxical LFLGAS: 139 (29)
-
36*
Sato et al. (2019) ROS 235 128 107 107 80 [73–85] 61 (26) - 0.75 [0.65–0.92] 25 [20–33] 22±7 29 [23–37] Classical LFLGAS 172 (74) 27.6 [8.4-44.4]